<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NEFAZODONE</span><br/>(nef-a-zo'done)<br/><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">antidepressant</span>; <span class="classification">selective serotonin reuptake inhibitor (ssri)</span><br/><b>Prototype: </b>Fluoxetine HCl<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg, 150 mg, 200 mg, 250 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Antidepressant with a dual mechanism of action. Inhibits neuronal serotonin (5-HT<sub>1</sub>) reuptake and also possesses 5-HT<sub>2</sub> antagonist properties. It is unrelated to tricyclic, <small>MAOI</small>, or other antidepressants.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antidepressant effects with minimal cardiovascular effects, fewer anticholinergic effects, less sedation, and less sexual
         dysfunction than other antidepressants.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of depression.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to nefazodone or alcohol; hepatic disease, hepatitis, jaundice; pregnancy (category C), lactation; mania;
         severe restlessness, suicidal ideation; surgery, neonates.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults, women of childbearing age; history of seizure disorders, seizures; renal or hepatic impairment; recent MI, unstable
         cardiac disease; hypotension; angina, stroke, hypovolemia, dehydration, ECT therapy. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg b.i.d., may need to increase up to 300600 mg/d in 23 divided doses<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 50 mg b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not give within 14 d of discontinuation of an <small>MAO INHIBITOR</small>.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Anaphylactic reactions, angioedema. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache, dizziness, drowsiness,</span> asthenia, tremor, insomnia, agitation, anxiety. <span class="typehead">GI:</span> Dry mouth, constipation, nausea, liver toxicity. <span class="typehead">Special Senses:</span> Visual disturbances, blurred vision, scotomata. <span class="typehead">Endocrine:</span> Galactorrheas, gynecomastia, serotonin syndrome. <span class="typehead">Skin:</span>
<span class="speceff-life">Stevens-Johnson syndrome</span>, <span class="speceff-life">liver failure</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May cause confusion, delirium, coma, seizures, or hyperthermia with <span class="classification">maoi</span>s; may increase plasma levels of some <span class="classification">benzodiazepines</span>, including <b>alprazolam</b> and <b>triazolam.</b> May decrease plasma levels and effects of <b>propranolol.</b> May increase levels and toxicity of <b>buspirone,</b>
<b>carbamazepine,</b>
<b>cilostazol,</b>
<b>digoxin;</b> reports of QTc prolongation and ventricular arrhythmias with <b>pimozide;</b> increased risk of rhabdomyolysis with <b>lovastatin,</b>
<b>simvastatin;</b> may cause <b>serotonin</b> syndrome with other <span class="classification">ssri</span>s; increase risk of <b>ergotamine</b> toxicity with <b>dihydroergotamine, ergotamine.</b>
<span class="typehead">Herbal:</span>
<b>St. John's wort</b> may cause <b>serotonin</b> syndrome (headache, dizziness, sweating, agitation). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 1 wk. <span class="typehead">Peak:</span> 35 wk. <span class="typehead">Metabolism:</span> Metabolized in liver to at least two active metabolites. <span class="typehead">Half-Life:</span> Nefazodone 3.5 h, metabolites 233 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for worsening of depression or emergence of suicidal ideation.</li>
<li>Evaluate concurrent drugs for possible interactions.</li>
<li>Monitor patients with a history of seizures for increased activity.</li>
<li>Assess safety, as dizziness and drowsiness are common adverse effects.</li>
<li>Lab tests: Monitor periodically liver function and CBC during long-term therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that significant improvement in mood may not occur for several weeks following initiation of therapy.</li>
<li>Do not drive or engage in potentially hazardous activities until response to the drug is known.</li>
<li>Report changes in visual acuity.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>